Centro de Investigación Genética y Genómica, Facultad de Ciencias de la Salud Eugenio Espejo, Universidad UTE, 170129 Quito, Ecuador.
Latin American Network for Implementation and Validation of Clinical Pharmacogenomics Guidelines (RELIVAF-CYTED), Madrid, Spain.
Genes (Basel). 2020 Jul 21;11(7):834. doi: 10.3390/genes11070834.
Telomere maintenance mechanisms (TMM) are used by cancer cells to avoid apoptosis, 85-90% reactivate telomerase, while 10-15% use the alternative lengthening of telomeres (ALT). Due to anti-telomerase-based treatments, some tumors switch from a telomerase-dependent mechanism to ALT; in fact, the co-existence between both mechanisms has been observed in some cancers. Although different elements in the ALT pathway are uncovered, some molecular mechanisms are still poorly understood. Therefore, with the aim to identify potential molecular markers for the study of ALT, we combined in silico approaches in a 411 telomere maintenance gene set. As a consequence, we conducted a genomic analysis of these genes in 31 Pan-Cancer Atlas studies from The Cancer Genome Atlas and found 325,936 genomic alterations; from which, we identified 20 genes highly mutated in the cancer studies. Finally, we made a protein-protein interaction network and enrichment analysis to observe the main pathways of these genes and discuss their role in ALT-related processes, like homologous recombination and homology directed repair. Overall, due to the lack of understanding of the molecular mechanisms of ALT cancers, we proposed a group of genes, which after ex vivo validations, could represent new potential therapeutic markers in the study of ALT.
端粒维持机制 (TMM) 被癌细胞用于避免细胞凋亡,85-90%重新激活端粒酶,而 10-15% 使用端粒的替代性延长 (ALT)。由于基于抗端粒酶的治疗,一些肿瘤从依赖端粒酶的机制转变为 ALT;事实上,在一些癌症中已经观察到这两种机制同时存在。尽管揭示了 ALT 途径中的不同元件,但一些分子机制仍知之甚少。因此,为了鉴定 ALT 研究的潜在分子标志物,我们在一个包含 411 个端粒维持基因的集合中结合了计算方法。结果,我们对来自癌症基因组图谱的 31 项泛癌症图谱研究中的这些基因进行了基因组分析,发现了 325,936 个基因组改变;其中,我们鉴定了在癌症研究中高度突变的 20 个基因。最后,我们构建了蛋白质-蛋白质相互作用网络和富集分析,以观察这些基因的主要途径,并讨论它们在 ALT 相关过程中的作用,如同源重组和同源定向修复。总的来说,由于对 ALT 癌症的分子机制缺乏了解,我们提出了一组基因,这些基因在体外验证后,可能成为 ALT 研究中新的潜在治疗标志物。